
Mosaad M El Gammal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4411831/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic significance of miRâ€21, miRâ€141, miRâ€18a and miRâ€221 as novel biomarkers in prostate cancer among Egyptian patients. Andrologia, 2019, 51, e13384.	2.1	17
2	Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e281-e290.	0.4	10
3	Prognostic Significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in Patients With Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 156-167.	0.4	9
4	Treatment outcomes of female germ cell tumors: The Egyptian National Cancer Institute experience. Journal of the Egyptian National Cancer Institute, 2014, 26, 103-108.	1.5	4
5	Altered Expression of MicroRNAs in the Bone Marrow of Multiple Myeloma Patients and their Relationship to Cytogenetic Aberrations. Current Pharmaceutical Biotechnology, 2020, 21, 1394-1401.	1.6	4
6	Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e406-e413.	0.4	3
7	High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and elimination. Journal of Chemotherapy, 2022, 34, 381-390.	debayed	3
8	Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 459-467.	0.4	1